Home
About Us
About Boan
Culture
Our History
Our Team
Responsibility
R&D
Technology platform
Boan Product Pipeline
Intellectual Property
Production capacity
Products
News
Careers
People Strategy
Employee Stories
Development
Job Opportunities
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Contact us
简
/
繁
/
EN
Investors
(02186.HK)
HK$
➚
%
Volume(M)
0thousand
Turnover(HK $)
0thousand
Data as of:
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Year
2022
2023
2024
2025
Search
16
2024-07
Acceptance of BLA in China for Aflibercept Intravitreous Injection (BA9101)
02
2024-07
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
04
2024-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
31
2024-05
Poll Results of the Annual General Meeting Held on 31 May 2024
27
2024-05
Acceptance of BLA in China for Dulaglutide Injection (BA5101)
27
2024-05
Denosumab Injection (Boluojia) for Oncology Indications Approved for Marketing by NMPA
06
2024-05
Monthly Return of Equity Issuer on Movements in Securities for The Month Ended 30 April 2024
29
2024-04
Form of Proxy for Use at Annual General Meeting to Be Held on 31 May 2024 (Applicable to Holders of H Shares)
29
2024-04
Notice of Annual General Meeting
29
2024-04
(1) 2023 Report of The Board of Directors (2) 2023 Report of The Board of Supervisors (3) 2023 Annual Report (4) Proposed Re-Election of Directors of The Second Session of The Board (5) Proposed Re-Election of Shareholder Representative Supervisors of The
1
2
3
4
5